<?xml version="1.0" encoding="UTF-8"?>
<p>Another relevant finding was that most symptomatic bDMARD-using patients had a shorter CHIK-related symptom duration than controls, with only 28% suffering symptoms beyond three months. When analyzing patients separately by immunobiological class, this positive result was only statistically significant in the group using anti-TNF drugs. The percentage of chronicity presented by controls was similar to the literature data, with approximately 50% of patients persisting with joint complaints for more than three months [
 <xref rid="B3" ref-type="bibr">3</xref>, 
 <xref rid="B21" ref-type="bibr">21</xref>].
</p>
